Hims & Hers Health CLO Sold 2,572 Shares at $58.7 Each on July 28.

Hims & Hers Health, Inc. (HIMS) has announced that its Chief Legal Officer, Boughton Soleil, has recently sold 2,572 shares of the company's stock at a price of $58.7 per share on July 28, 2025.

Hims & Hers Health, Inc. (HIMS) has seen its stock value fluctuate significantly in recent months, with a notable downturn of -2.42% on July 29, 2025, amid a sector-wide health-tech downturn. The company is currently facing class action lawsuits alleging misleading statements about its collaboration with Novo Nordisk, impacting access to weight-loss drug Wegovy. These suits involve stocks purchased between April 29 and June 23, 2025, and include claims of securities fraud [1].

Adding to the turmoil, Hims & Hers Health's Chief Legal Officer, Boughton Soleil, recently sold 2,572 shares of the company's stock at a price of $58.7 per share on July 28, 2025. While the sale may not indicate a definitive exit strategy, it does suggest internal turbulence and potential concerns among key executives. The sale, worth approximately $149,000, follows a period of heightened legal scrutiny and investor uncertainty [2].

The company's financial health is also under scrutiny. Despite a robust revenue of over $1 billion and a high gross margin of 77%, Hims & Hers Health faces challenges with a pretax profit margin at -2% for Q1 2025. Stock values have been volatile, ranging between $50 and $59, with recent legal issues exacerbating market skepticism [1].

Investors are now grappling with the potential fallout from the legal challenges and halted partner collaboration. The company's access to products like Wegovy, a major concern in the market discussions, is threatened by these developments. As the legal battles unfold, investors will closely monitor the company's ability to navigate these challenges and restore market confidence [1].

References:
[1] https://www.timothysykes.com/news/hims-hers-health-inc-hims-news-2025_07_29/
[2] https://www.morningstar.com/news/pr-newswire/20250729ny39030/levi-korsinsky-reminds-hims-hers-health-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-25-2025-hims